Gaudium IVF & Women Health Ltd. (Mainboard)

Founded in 2015 by Dr. Manika Khanna, Gaudium IVF is a leading pan-India provider of Assisted Reproductive Technology (ART) and fertility services. It operates through a highly efficient Hub-and-Spoke model, allowing it to serve both urban centers and regional markets effectively.

Business Verticals

• Core Fertility Treatments: IVF, ICSI, IUI, and Ovulation Induction.

• Male Infertility Services: Advanced sperm retrieval (TESA) and specialized diagnostics.

• Fertility Preservation: Egg, sperm, and embryo freezing.

• Gynaecological Care: Advanced endoscopic surgeries and maternity services at its day-care facilities.

• Ancillary Services: Pharmaceutical sales through its subsidiary and international patient consultancy.

Track Record

• Network: Operates 7 full-service hubs (Delhi, Mumbai, Bengaluru, Patna, Ludhiana, Srinagar) and 28 spokes across India.

• Global Reach: Serves patients from over 30 countries, including the UK, USA, and Canada.

• Financial Growth: Total income rose to ₹70.96 Cr in FY25 (up from ₹47.89 Cr in FY24) with a PAT of ₹19.13 Cr.

• Clinical Excellence: Recognized for high success rates in "previously failed IVF" cases.

Gaudium IVF & Women Health Ltd IPO GMP

As of February 15, 2026, the Grey Market Premium (GMP) has not yet opened. GMP typically starts fluctuating once the official price band is declared.

Note: Being the first in its sector, the market response will likely set a benchmark for other upcoming healthcare IPOs like Indira IVF.

Gaudium IVF & Women Health Ltd IPO Allotment Status

The allotment is scheduled for Feb 25, 2026.

Check Gaudium IVF Allotment Status To check your status, visit: [Check Allotment Status Here]

You can verify your status via:

• Registrar's website (Bigshare Services Pvt Ltd)

• BSE/NSE official portals

• Using your PAN number or Application ID

Strengths

• First-Mover Advantage: First IVF-focused company to list in India, capturing significant investor interest in a growing niche.

• High Efficiency Model: The Hub-and-Spoke model minimizes capital expenditure while maximizing patient reach.

• Strong Profit Margins: Boasts healthy PAT margins (approx. 27% in FY25) and a robust ROE of 41.3%.

• Trusted Brand: Lead by award-winning specialist Dr. Manika Khanna with over 16 years of clinical experience.

Weakness

• Regulatory Risks: The sector is strictly governed by the ART (Regulation) Act, 2021; any changes in compliance could impact operations.

• Legal/Tax Contingencies: The company has outstanding income tax demands of approximately ₹30.91 crores under appeal.

• Competition: Faces rising competition from larger hospital chains expanding into fertility and well-funded rivals like Indira IVF.

• High Concentration: A large portion of revenue is still driven by its primary hubs in North India.

How the Company Will Use IPO Money

The fresh issue proceeds of approx. ₹70–80 crores will be utilized for:

• Expansion: ₹50.00 crores for establishing 19 new IVF centers across India.

• Debt Repayment: ₹20.00 crores for the repayment/pre-payment of outstanding loans.

• General Corporate Purposes: Addressing operational expenses and strategic initiatives.

Gaudium IVF & Women Health Ltd Lead Manager

Sarthi Capital Advisors Private Limited

Gaudium IVF & Women Health Ltd Address

Gaudium IVF & Women Health Limited

Registered Office: B1/51, Janak Puri, B-1, New Delhi – 110058, India

Phone: +91 011-4885 8585

E-mail: compliance@gaudiumivfcentre.com

Website: https://www.gaudiumivfcentre.com/

Gaudium IVF Registrar

Bigshare Services Private Limited

Address: S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Andheri (East), Mumbai - 400 093

Phone: +91-22-6263 8200

Email: ipo@bigshareonline.com